Economic burden of chronic migraine in OECD countries: a systematic review

Health Economics Review

Review

Saval Khanal¹  Hema Mistry²  Vibhu Paudyal³  Alyaa Eltrafi³  Sunil Shrestha⁴  Ali Ahmed⁵ 

[1] Department of Pharmacy Practice, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan;Health Economics Consulting, Norwich Medical School, University of East Anglia, Bob Champion Research & Education Building, UEA Research Park Rosalind Franklin Rd, NR4 7UQ, Norwich, UK;School of Pharmacy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK;School of Pharmacy, Monash University Malaysia, 47500, Bandar Sunway, Malaysia;School of Pharmacy, Monash University Malaysia, 47500, Bandar Sunway, Malaysia;Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK;

关键词: Chronic migraine;    Cost of illness;    Economic burden;    Direct costs;    Indirect costs;    Intangible costs;    Productivity losses;    Systematic review;    Healthcare policy;    Resource allocation;   

DOI  :  10.1186/s13561-023-00459-2

 received in 2022-12-30, accepted in 2023-08-22,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundChronic migraine (CM) is a significant neurological condition affecting a substantial portion of the global population. The economic burden of CM includes both direct healthcare costs and indirect costs resulting from productivity losses and intangible impacts on patients’ quality of life. However, there is limited research that comprehensively evaluates all cost components associated with CM, highlighting the need for a systematic review.MethodsWe conducted a systematic literature search in databases including MEDLINE, Embase, and CINAHL to identify studies estimating the cost of illness of chronic migraines. The search was restricted to English language articles published from inception to October 2021, and only findings from Organisation for Economic Co-operation and Development (OECD) countries were included. Methodology features and key findings were extracted from the studies, and reported costs were converted to GBP for cross-country comparisons.ResultsThirteen cost-of-illness studies on CM from various OECD countries were included in this review. The studies demonstrated substantial variations in monetary estimates, but consistently highlighted the considerable economic burden of CM. Direct costs, particularly hospitalisation and medication expenses, were identified as the highest contributors. However, indirect costs, such as productivity losses due to absenteeism and presenteeism, were often underexplored in the reviewed studies. Additionally, intangible costs related to emotional and social impacts on patients were largely overlooked.ConclusionChronic migraine imposes a significant economic burden on individuals, healthcare systems, and society. Policymakers and healthcare stakeholders should consider both direct and indirect cost components, as well as intangible costs, in developing targeted strategies for effective CM management and resource allocation. Further research focusing on comprehensive cost assessments and sensitivity analyses is needed to enhance the understanding of CM’s economic implications and inform evidence-based healthcare policy decisions. Addressing these research gaps can alleviate the economic burden of CM and improve patient outcomes.

【 授权许可】

CC BY   
© Springer-Verlag GmbH Germany, part of Springer Nature 2023